Actinium Pharmaceuticals, Inc. — Director's Dealing 2022

Jul 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2022-07-01

Reporting Person: Shetty Ajit (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-01	Stock Option (Right to Buy)	$4.96	A	72156	Acquired	2032-07-01	Common Stock (72156)	Direct

Footnotes

F1: This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant.

F2: Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested.